Rib-X Pharmaceuticals, Inc. Announces New Executive Leadership and Board of Directors Appointments
Published: Apr 03, 2013
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today new appointments to the executive team and Board of Directors. Mary Szela has been appointed as Chief Executive Officer, bringing 25 years of experience as an accomplished pharmaceutical executive to the Company. Eugene Sun, M.D., has been appointed Executive Vice President, Research and Development, bringing clinical and scientific leadership and expertise to the Company. Michael Kenston has been appointed Chief Commercial Officer, bringing a broad range of commercial, sales and business development experience to the Company. Rib-X also announced today that director, Thomas Koestler, Ph.D., has been appointed Chairman of the Board. Ms. Szela, who joined the Company’s Board in January, will remain a director.